Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 13/20 | 0.78 |
| ▸ | EED | O75530 | 2/20 | 0.70 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.70 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.70 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.70 |
| ▸ | EZH1 | Q92800 | 8/20 | 0.58 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.58 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.58 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19503400 | 0.94 | EZH2 (0.80) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL28521908 | 0.89 | EZH2 (0.87) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL28516505 | 0.88 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL23863694 | 0.84 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL23863706 | 0.84 | EZH2 (0.64) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL15393260 | 0.83 | EZH2 (1.00) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL23863738 | 0.80 | EZH2 (0.72) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL24227159 | 0.80 | EZH2 (0.62) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17734365 | 0.79 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21917051 | 0.79 | EZH2 (0.65) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |